Document and Entity Information
Document and Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Mar. 22, 2024 | Jun. 30, 2023 | |
Document Information [Line Items] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2023 | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Entity Interactive Data Current | Yes | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Registrant Name | BIOATLA, INC. | ||
Entity Central Index Key | 0001826892 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Title of 12(b) Security | Common Stock, $0.0001 par value per share | ||
Trading Symbol | BCAB | ||
Security Exchange Name | NASDAQ | ||
Entity Public Float | $ 91 | ||
Entity Current Reporting Status | Yes | ||
Entity Shell Company | false | ||
Entity File Number | 001-39787 | ||
Entity Tax Identification Number | 85-1922320 | ||
Entity Address, Address Line One | 11085 Torreyana Road | ||
Entity Address, City or Town | San Diego | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 92121 | ||
City Area Code | 858 | ||
Local Phone Number | 558-0708 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
ICFR Auditor Attestation Flag | false | ||
Documents Incorporated by Reference | Part III incorporates by reference certain information from the registrant’s definitive proxy statement (the “Proxy Statement”) relating to its 2024 Annual Meeting of Stockholders. The Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates. | ||
Document Financial Statement Error Correction [Flag] | false | ||
Auditor Name | Ernst & Young LLP | ||
Auditor Location | San Diego, CaliforniaMarch | ||
Auditor Firm ID | 42 | ||
Common Stock | |||
Document Information [Line Items] | |||
Entity Common Stock, Shares Outstanding | 48,096,717 | ||
Common Class B | |||
Document Information [Line Items] | |||
Entity Common Stock, Shares Outstanding | 0 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 111,471 | $ 215,507 |
Prepaid expenses and other current assets | 4,935 | 4,924 |
Total current assets | 116,406 | 220,431 |
Property and equipment, net | 1,603 | 2,728 |
Operating lease right-of-use-asset, net | 1,495 | 2,423 |
Other assets | 154 | 154 |
Total assets | 119,658 | 225,736 |
Current liabilities: | ||
Accounts payable and accrued expenses | 26,720 | 21,610 |
Operating lease liabilities | 1,624 | 1,521 |
Total current liabilities | 28,344 | 23,131 |
Operating lease liabilities, less current portion | 836 | 2,460 |
Liability to licensor | 19,806 | 19,806 |
Total liabilities | 48,986 | 45,397 |
Commitments and contingencies (Note 6) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2022 and December 31, 2021; 0 shares issued and outstanding at December 31, 2022 and December 31, 2021 | 0 | 0 |
Common stock value | 5 | 5 |
Additional paid-in capital | 486,930 | 473,135 |
Accumulated deficit | (416,263) | (292,801) |
Total stockholders' equity | 70,672 | 180,339 |
Total liabilities and stockholders' equity | $ 119,658 | $ 225,736 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
Preferred Stock, Shares Authorized | 200,000,000 | 200,000,000 |
Preferred Stock, Shares Issued | 0 | 0 |
Preferred Stock, Shares Outstanding | 0 | 0 |
Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
Common Stock, Shares Authorized | 350,000,000 | 350,000,000 |
Common Stock, Shares, Issued | 48,077,599 | 46,336,166 |
Common Stock, Shares, Outstanding | 48,077,599 | 46,336,166 |
Common Class B | ||
Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
Common Stock, Shares Authorized | 15,368,569 | 15,368,569 |
Common Stock, Shares, Issued | 0 | 1,211,959 |
Common Stock, Shares, Outstanding | 0 | 1,211,959 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development expense | $ 103,731 | $ 79,347 |
General and administrative expense | 25,956 | 28,793 |
Total operating expenses | 129,687 | 108,140 |
Loss from operations | (129,687) | (108,140) |
Other income (expense): | ||
Interest income | 6,312 | 1,648 |
Other income (expense) | (87) | 10 |
Total other income (expense) | 6,225 | 1,658 |
Consolidated net loss and comprehensive loss | $ (123,462) | $ (106,482) |
Net loss per common share, basic | $ (2.58) | $ (2.74) |
Net loss per common share, diluted | $ (2.58) | $ (2.74) |
Weighted-average shares of common stock outstanding, basic | 47,777,568 | 38,927,268 |
Weighted-average shares of common stock outstanding, diluted | 47,777,568 | 38,927,268 |
Consolidated Statements of Conv
Consolidated Statements of Convertible Preferred Stock and Stockholders / Members Equity (Deficit) - USD ($) $ in Thousands | Total | Class B Common Stock | Common Stock | Additional Paid-in Capital | Accumulated deficit |
Balance at Dec. 31, 2021 | $ 210,821 | $ 4 | $ 397,136 | $ (186,319) | |
Balance, shares at Dec. 31, 2021 | 1,492,059 | 35,799,233 | |||
Issuance of common stock, net of issuance costs | 61,682 | $ 1 | 61,681 | ||
Issuance of common stock, net of issuance costs, shares | 9,745,128 | ||||
Issuance of common stock under equity incentive plans, net of shares withheld for taxes, shares | 364,141 | ||||
Issuance of common stock for Employee Stock Purchase Plan | 289 | 289 | |||
Issuance of common stock for Employee Stock Purchase Plan, shares | 147,564 | ||||
Taxes related to net share settlement of equity awards | (534) | (534) | |||
Conversion of Class B Common Stock, Shares | (280,100) | 280,100 | |||
Conversion of Class B Common Stock | 0 | 0 | |||
Stock-based compensation | 14,563 | 14,563 | |||
Net Income (Loss) | (106,482) | (106,482) | |||
Balance at Dec. 31, 2022 | 180,339 | $ 5 | 473,135 | (292,801) | |
Balance, shares at Dec. 31, 2022 | 1,211,959 | 46,336,166 | |||
Issuance of common stock under equity incentive plans, net of shares withheld for taxes, shares | 318,634 | ||||
Issuance of common stock for Employee Stock Purchase Plan | 336 | 336 | |||
Issuance of common stock for Employee Stock Purchase Plan, shares | 165,550 | ||||
Issuance of common stock for director compensation(value) | 107 | 107 | |||
Issuance of common stock for director compensation(shares) | 45,290 | ||||
Taxes related to net share settlement of equity awards | (192) | (192) | |||
Conversion of Class B Common Stock, Shares | (1,211,959) | 1,211,959 | |||
Conversion of Class B Common Stock | 0 | ||||
Stock-based compensation | 13,544 | 13,544 | |||
Net Income (Loss) | (123,462) | (123,462) | |||
Balance at Dec. 31, 2023 | $ 70,672 | $ 5 | $ 486,930 | $ (416,263) | |
Balance, shares at Dec. 31, 2023 | 48,077,599 |
Consolidated Statements of Co_2
Consolidated Statements of Convertible Preferred Stock and Stockholders / Members Equity (Deficit) (Parenthetical) $ in Thousands | 12 Months Ended |
Dec. 31, 2022 USD ($) | |
Payments of Stock Issuance Costs | $ 3,318 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Cash flows from operating activities | ||
Net Income (Loss) | $ (123,462) | $ (106,482) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 1,221 | 1,199 |
Loss on disposal of property and equipment | 2 | 13 |
Stock-based compensation | 13,544 | 14,563 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other assets | (11) | (2,611) |
Accounts payable and accrued expenses | 5,284 | 3,411 |
Right-of-use assets and lease liabilities, net | (593) | (513) |
Net cash used in operating activities | (104,015) | (90,420) |
Cash flows from investing activities | ||
Purchases of property and equipment | (98) | (268) |
Proceeds from sale of property and equipment | 0 | 3 |
Net cash used in investing activities | (98) | (265) |
Cash flows from financing activities | ||
Proceeds from issuance of common stock, net of issuance costs | 0 | 61,682 |
Proceeds from issuance of common stock under Employee Stock Purchase Plan | 336 | 289 |
Payments for taxes related to net settlement of equity awards | (259) | (758) |
Net cash provided by financing activities | 77 | 61,213 |
Net decrease in cash and cash equivalents | (104,036) | (29,472) |
Cash and cash equivalents, beginning of period | 215,507 | 244,979 |
Cash and cash equivalents, end of period | 111,471 | 215,507 |
Supplemental disclosure of non-cash investing and financing activities | ||
Property and equipment additions included in accounts payable and accrued expenses | 0 | 1 |
Tax related to net settlement of equity award included in accounts payable and accrued expenses | $ 6 | $ 67 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Pay vs Performance Disclosure | ||
Net Income (Loss) | $ (123,462) | $ (106,482) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Dec. 31, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Organization and summary of sig
Organization and summary of significant accounting policies | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Organization and summary of significant accounting policies | 1. Organization and summary of significant accounting policies Organization BioAtla, LLC was formed in Delaware in March 2007 and was converted to a Delaware corporation in July 2020 and renamed BioAtla, Inc. (the “Company”). The Company has a proprietary platform for creating biologics, including its conditionally active biologics (“CAB” or “CABs”). CABs have been designed to be active only under certain conditions found in diseased tissue, while remaining inactive in normal tissue. The Company is currently in clinical development of its two lead CAB antibody drug conjugates (“CAB ADC”) targeting AXL and ROR2 receptors, its CAB immune-oncology antibody targeting CTLA-4, and its CAB bispecific antibody targeting EpCAM. Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). BioAtla, Inc. is a single legal entity with no consolidated variable interest entities ("VIEs") or subsidiaries (see Note 8). Liquidity and Going Concern The Company has incurred cumulative operating losses and negative cash flows from operations since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the development of its product candidates. As of December 31, 2023, the Company had an accumulated deficit of $ 416.3 million . The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. In January 2023, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Jefferies LLC pursuant to which the Company may, from time to time at its sole discretion, sell shares of the Company’s common stock, with aggregate gross sales proceeds of up to $ 100.0 million. The Company has not sold any shares of its common stock under the Sales Agreement as of December 31, 2023. Management is required to perform a two-step analysis of the Company’s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2). Management’s assessment included the preparation of cash flow forecasts resulting in management’s conclusion that there is not substantial doubt about the Company’s ability to continue as a going concern as its current cash and cash equivalents will be sufficient to fund the Company’s operations for a period of at least one year from the issuance date of these financial statements. Variable Interest Entities (“VIE”) The Company consolidates entities in which it has a controlling financial interest. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a voting interest entity or a VIE. VIEs are entities in which (i) the total equity investment at risk is sufficient to enable the entity to finance its activities independently, (ii) the equity holders have the power to direct the activities of the entity that most significantly impact its economic performance, the obligation to absorb the losses of the entity and the right to receive the residual returns of the entity and (iii) the legal entity is structured with substantive voting rights. A VIE is an entity that lacks one or more of the characteristics of a voting interest entity. The Company has a controlling financial interest in a VIE when the Company has a variable interest or interests that provide it with (i) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company evaluates its relationships with its VIEs on an ongoing basis to determine whether or not it has a controlling financial interest (see Note 8). Use of Estimates The Company’s financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development costs, equity-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash equivalents. Cash equivalents consist of highly rated securities including U.S. Government and U.S. Treasury money market funds, which are unrestricted as to withdrawal or use. The cash and cash equivalents balance as of December 31, 2023 and 2022 includes $ 50.4 million and $ 0 , respectively, invested in U.S. Government and U.S. Treasury money market funds. Concentrations of Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and may invest cash that is not required for immediate operating needs in highly liquid instruments that bear minimal risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Property and Equipment Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful life of the related assets. Leasehold improvements are stated at cost and amortized on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful life of the leasehold improvements. Repairs and maintenance costs are charged to expense as incurred and expenditures that materially extend the useful lives of assets are capitalized. Impairment of Long-Lived Assets The Company reviews long-lived assets, such as property and equipment, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Fair value would be assessed using discounted cash flows or other appropriate measures of fair value. The Company has no t recognized any impairment losses for the years ended December 31, 2023 and 2022 . Leases The Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. The Company’s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease right-of-use (“ROU”) assets are based on the corresponding lease liability adjusted for any lease payments made at or before commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line basis over the lease term. Variable lease costs are not included in the calculation of the ROU asset and the related lease liability and are recognized as incurred. The Company has a single lease agreement with lease and non-lease components, which are accounted for as a single lease component. Payments for short-term leases, defined as leases with a term of twelve months or less, are expensed on a straight-line basis over the lease term. The Company does not currently have any short-term leases. Operating leases are included in operating lease right-of-use assets, operating lease liabilities, and operating lease liabilities, non-current on the Company’s balance sheets. The Company does not have any finance leases. Revenue Recognition The Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. The Company considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. A customer is a party that has entered into a contract with the Company, where the purpose of the contract is to obtain a product or a service that is an output of the Company’s ordinary activities in exchange for consideration. To be considered a contract, (i) the contract must be approved (in writing, orally, or in accordance with other customary business practices), (ii) each party’s rights regarding the product or the service to be transferred can be identified, (iii) the payment terms for the product or the service to be transferred can be identified, (iv) the contract must have commercial substance (that is, the risk, timing or amount of future cash flows is expected to change as a result of the contract), and (v) it is probable that the Company will collect substantially all of the consideration to which it is entitled to receive in exchange for the transfer of the product or the service. A performance obligation is defined as a promise to transfer a product or a service to a customer. The Company identifies each promise to transfer a product or a service (or a bundle of products or services, or a series of products and services that are substantially the same and have the same pattern of transfer) that is distinct. A product or a service is distinct if both (i) the customer can benefit from the product or the service either on its own or together with other resources that are readily available to the customer and (ii) the Company’s promise to transfer the product or the service to the customer is separately identifiable from other promises in the contract. Each distinct promise to transfer a product or a service is a unit of accounting for revenue recognition. If a promise to transfer a product or a service is not separately identifiable from other promises in the contract, such promises should be combined into a single performance obligation. The transaction price is the amount of consideration the Company is entitled to receive in exchange for the transfer of control of a product or a service to a customer. To determine the transaction price, the Company considers the existence of any significant financing component, the effects of any variable elements, noncash consideration and consideration payable to the customer. If a significant financing component exists, the transaction price is adjusted for the time value of money. If an element of variability exists, the Company must estimate the consideration it expects to receive and uses that amount as the basis for recognizing revenue as the product or the service is transferred to the customer. There are two methods for determining the amount of variable consideration: (i) the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts, and (ii) the mostly likely amount method, which identifies the single most likely amount in a range of possible consideration amounts. If a contract has multiple performance obligations, the Company allocates the transaction price to each distinct performance obligation in an amount that reflects the consideration the Company is entitled to receive in exchange for satisfying each distinct performance obligation. For each distinct performance obligation, revenue is recognized when the Company transfers control of the product or the service applicable to such performance obligation. In those instances where the Company first receives consideration in advance of satisfying its performance obligation, the Company classifies such consideration as deferred revenue until (or as) the Company satisfies such performance obligation. In those instances where the Company first satisfies its performance obligation prior to its receipt of consideration, the consideration is recorded as accounts receivable. The Company expenses incremental costs of obtaining and fulfilling a contract as incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as contract assets if they are incremental to the contract and amortized to expense proportionate to revenue recognition of the underlying contract. Research and Development Expenses The Company’s activities have largely consisted of research and development efforts related to developing our CAB programs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to expense as incurred. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in the accompanying balance sheets as prepaid or accrued expenses. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. As of December 31, 2023, the Company has accrued $ 12.5 million related to clinical trial costs. The Company has entered into contracts related to its clinical trials with clinical research organizations. The Company reviews and accrues clinical trial costs based on work performed, which relies on estimates and assumptions of total trial management costs, sites activated, patients enrolled, and number of patient visits. The Company follows this method since reasonably dependable estimates of the costs applicable to clinical trials can be made. Accrued clinical trial costs are subject to revisions as the trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. A modification in the protocol of a clinical trial or cancellation of a trial could result in a material change to the Company's results of operations. Patent Costs Costs related to filing and pursuing patent applications are recorded as general and administrative expenses and expensed as incurred since recoverability of such expenditures is uncertain. Stock-Based Compensation Stock-based compensation expense represents the grant date fair value of equity awards, consisting of stock options, restricted stock units (“RSUs”) and employee stock purchase plan rights, over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and employee stock purchase plan rights using the Black-Scholes option pricing model. Prior to the Company’s IPO, the fair value of RSUs was based on the estimated fair value of the underlying common stock on the date of grant and, subsequent to the Company’s IPO, the fair value is based on the closing sales price of the Company’s common stock on the date of grant. Equity award forfeitures are recognized as they occur. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as income in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, exclusive of reversing temporary difference, tax-planning strategies, and the results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 % likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss. Net Loss Per Share Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of RSUs, common stock options outstanding under the Company’s stock option plan, and contingently issuable shares under the BioAtla, Inc. Employee Stock Purchase Plan (the “ESPP”). Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalents): December 31, 2023 2022 Common stock options 6,273,507 2,736,918 Restricted stock units 99,104 510,039 ESPP Shares 57,253 13,370 Total 6,429,864 3,260,327 Recent Accounting Pronouncements In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. |
Balance sheet details
Balance sheet details | 12 Months Ended |
Dec. 31, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Balance sheet details | 2. Balance sheet details Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2023 2022 Prepaid research and development $ 4,615 $ 4,385 Other prepaid expenses and current assets 320 539 Total $ 4,935 $ 4,924 Property and equipment consist of the following (in thousands): December 31, Useful life (years) 2023 2022 Furniture, fixtures and office equipment 3 - 7 $ 1,721 $ 2,140 Laboratory equipment 5 2,280 2,265 Leasehold improvements 2 - 3 3,680 3,687 7,681 8,092 Less accumulated depreciation and amortization ( 6,078 ) ( 5,364 ) Total $ 1,603 $ 2,728 Accounts payable and accrued expenses consist of the following (in thousands): December 31, 2023 2022 Accounts payable $ 3,819 $ 4,231 Accrued compensation 3,790 3,451 Accrued research and development 18,246 12,649 Other accrued expenses 865 1,279 Total $ 26,720 $ 21,610 |
Fair value measurements
Fair value measurements | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair value measurements | 3. Fair value measurements The carrying amounts of the Company’s current financial assets and current financial liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of December 31, 2023 and December 31, 2022 , the Company had no financial assets or liabilities measured at fair value on a recurring basis. The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets. Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. As of December 31, 2023 and 2022, the Company had $ 50.4 million and $ 0 , respectively, invested in U.S. Government and U.S. Treasury money market funds which are recorded as cash equivalents and represent a Level 1 measurement within the fair value hierarchy. None of the Company’s non-financial assets and liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Leases | . Leases The Company has a single operating lease for its corporate headquarters and laboratory space in San Diego, California. The lease expires in July 2025 and the Company has an option to extend the term of the lease for an additional five years . Additionally, the lease includes certain rent abatement, rent escalations, tenant improvement allowances and additional charges for common area maintenance and other costs. The components of lease expense included in the Company’s statements of operations and loss include (in thousands): Years ended December 31, 2023 2022 Operating lease expense $ 1,043 $ 1,043 Variable lease expense 544 460 Total lease expense, net $ 1,587 $ 1,503 Variable lease costs are primarily related to payments made to lessors for common area maintenance, property taxes, insurance, and other operating expenses. The Company did not have any short-term leases or finance leases for the year ended December 31, 2023. The weighted average remaining lease term and weighted average discount rate for operating leases were as follows: December 31, 2023 2022 Weighted average remaining lease term (in years) 1.5 2.5 Weighted average discount rate percentage 3.50 % 3.50 % Supplemental cash flow information related to leases under which the Company is the lessee was as follows (amounts in thousands): Years ended December 31, 2023 2022 Cash paid for amounts included in the measurement of operating leases $ 1,500 $ 1,555 Maturities of operating lease liabilities as of December 31, 2023 were as follows (in thousands): Years ending December 31: Operating 2024 $ 1,685 2025 845 Thereafter — Total future lease payments 2,530 Less imputed interest ( 70 ) Total operating lease liabilities $ 2,460 |
Commitments and contingencies
Commitments and contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and contingencies | . Commitments and contingencies From time to time, the Company may be subject to various claims and suits arising in the ordinary course of business. The Company is not currently a party to any legal proceedings the outcome of which the Company believes, if determined adversely to the Company, would individually or in the aggregate have a material adverse effect on the Company’s business, operating results or financial condition. |
Stockholders equity
Stockholders equity | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Stockholders equity (deficit) | 6. Stockholders’ equity Description of securities of Delaware corporation The Company is authorized to issue 200,000,000 shares of preferred stock, par value $ 0.0001 per share, 350,000,000 shares of common stock, par value $ 0.0001 per share, and 15,368,569 shares of Class B common stock, par value $ 0.0001 per share. Dividends Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of the Company’s common stock and Class B common stock are entitled to receive dividends only if declared from time to time by the Company’s board of directors out of assets which are legally available. Liquidation preferences Upon any liquidation, dissolution or winding-up of the Company, holders of the Company’s common stock and Class B common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Conversion Holders of the Company’s common stock have no conversion rights, while holders of the Company’s Class B common stock shall have the right to convert each share of Class B common stock into one share of common stock at such holder’s election, provided that as a result of such conversion, such holder would not beneficially own in excess of 4.99% of any class of the Company’s securities registered under the Securities Exchange Act of 1934 , as amended, unless otherwise as expressly provided for in the Company’s amended and restated certificate of incorporation. This ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B common stock upon 61 days’ notice to the Company. Voting rights Except as otherwise expressly provided in the Company’s amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by the Company’s stockholders, holders of the Company’s common stock are entitled to one vote per share of common stock, and holders of the Company’s Class B common stock are not entitled to any votes per share of Class B common stock, including for the election of directors. November 2022 Underwritten Offering On November 8, 2022, the Company completed a follow-on offering under its shelf registration statement on Form S-3 (File No. 333-262528) and a related prospectus supplement pursuant to which the Company issued an aggregate of 9,745,128 shares of its common stock to at a public offering price of $ 6.67 per share. The Company received aggregate net proceeds of $ 61.7 million fro m the offering after deducting underwriting discounts and commissions and other offering expenses. Common stock warrants The Company issued the warrants described below in 2016 in connection with certain advisory services. The warrants became exercisable upon the Company's IPO for a period of 365 and 450 days . Upon adoption of ASU No. 2018-07 on October 1, 2020, the measurement date of the warrants became fixed in accordance with the guidance, and such fair value was nominal since the warrants were deeply out-of-the-money. In December 2021, a total of 566,586 warrants with an exercise period of 365 days after the Company's IPO expired unexercised. The remaining 151,088 warrants with an exercise period of 450 days after the Company's IPO expired unexercised in March 2022. Accordingly, there are no remaining common stock warrants outstanding and exercisable at December 31, 2022 or December 31, 2023. Open market sale agreement In January 2023, BioAtla, Inc. (the “Company”) entered into an open market sale agreement under which the Company may offer and sell, from time to time in its sole discretion, shares of the Company’s common stock, par value $ 0.0001 per share, with aggregate gross sales proceeds of up to $ 100,000,000 through an “at the market” equity offering program under which Jefferies LLC will act as sales agent. No shares have been sold under the agreement to date. 2020 Equity Incentive Plan On October 29, 2020, the Company’s board of directors approved the adoption of the BioAtla, Inc. 2020 Equity Incentive Plan (the “2020 Plan”) and approved certain amendments to the 2020 Plan in December 2020. The Company’s stockholders approved the 2020 Plan, as amended, in December 2020. Under the 2020 Plan, the Company may grant awards of common stock to the Company’s employees, consultants and non-employee directors pursuant to option awards, stock appreciation rights awards, restricted stock awards, restricted stock unit awards, performance stock awards, performance stock unit awards and other stock-based awards. As of December 31, 2023 and 2022 , the total number of common shares authorized for issuance under the 2020 Plan was 9,196,970 and 7,658,509 , respectively. On January 1st of each year, commencing with the first January 1st following the effective date of the 2020 Plan, the shares authorized for issuance under the 2020 Plan shall be increased by a number of shares equal to the lesser of 4 % of the total number of shares outstanding on the immediately preceding December 31st and such lesser number of shares determined by the Company’s board of directors. The maximum term of the options granted under the 2020 Plan is no more than ten years . Awards under the 2020 Plan generally vest at 25 % one year from the vesting commencement date and ratably each month thereafter for a period of 36 months, subject to continuous service. On February 26, 2023, the Compensation Committee of the Company’s board of directors approved a modification to the Company’s 2020 Plan to allow vesting of RSUs or stock options, as applicable, subject to the grantee’s continued service to the Company and/or one of its subsidiaries as an employee, non-employee director, or independent contractor. Unvested RSUs totaling 139,730 shares and 574,244 unvested options which would have been forfeited under the original terms of the 2020 Plan will now continue to vest. The Company applied modification accounting to these awards which resulted in a decrease in fair value to these awards. The Company calculated compensation cost for the modified unvested awards of $ 416,000 related to the RSUs and $ 962,000 related to the options, and will recognize these amounts over the remaining requisite service periods. The modification also resulted in an increase to the term of 130,699 fully vested options for which $ 123,000 of incremental compensation cost was immediately recognized on the date of the modification. Stock-based compensation expense recognized for all equity awards under the 2020 Plan has been reported in the statements of operations and comprehensive loss as follows (in thousands): Years ended December 31, 2023 2022 Research and development $ 5,462 $ 5,419 General and administrative 8,082 9,144 Total $ 13,544 $ 14,563 Restricted stock units In December 2022, the Company’s board of directors approved an amendment to the Director Compensation Policy, which allows each director to elect to receive their quarterly director fees in the form of restricted stock in lieu of cash. Two board members elected to receive shares of restricted stock in lieu of cash. For the twelve months ended December 31, 2023 , the Company issued 45,290 shares of fully vested restricted stock to the two board members. Compensation expense was earned and recognized for these fully vested restricted stock grants in the amount of $ 0.1 million for the twelve months ended December 31, 2023. The following table summarizes RSU activity under the 2020 Plan for the years ended December 31, 2023 and 2022: Number of Weighted - Outstanding at December 31, 2021 975,046 $ — Granted — $ — Vested ( 446,260 ) $ 18.00 Forfeited ( 18,747 ) Outstanding at December 31, 2022 510,039 $ 18.00 Granted 45,290 $ 2.35 Vested ( 433,948 ) $ 16.37 Forfeited ( 22,277 ) $ 18.00 Outstanding at December 31, 2023 99,104 $ 18.00 As of December 31, 2023 , total unrecognized stock-based compensation expense for RSUs was $ 1.8 million, which is expected to be recognized over a remaining weighted-average period of approximately 0.7 years. Stock options The following table summarizes stock option activity under the 2020 Plan for the year ended December 31, 2023 and 2022 (in thousands, except share and per option data and years): Number of Weighted - Weighted - Aggregate Balance at December 31, 2021 1,086,902 $ 26.76 9.22 $ 991,495 Granted 1,718,200 $ 6.35 Exercised — $ — Forfeited ( 50,387 ) $ 21.64 Expired ( 17,797 ) $ 40.00 Balance at December 31, 2022 2,736,918 $ 13.82 8.82 $ 3,636,148 Granted 4,020,395 $ 3.74 Exercised — $ — Forfeited ( 371,439 ) $ 7.20 Expired ( 112,367 ) $ 20.96 Balance at December 31, 2023 6,273,507 $ 7.62 8.64 $ 74,680 Vested and expected to vest at December 31, 2023 6,273,507 $ 7.62 8.64 $ 74,680 Exercisable at December 31, 2023 1,429,449 $ 14.98 7.75 $ 2,007 As of December 31, 2023 , total unrecognized stock-based compensation cost for unvested common stock options was $ 15.6 million, which is expected to be recognized over a remaining weighted-average period of approximately 2.8 years. The weighted- average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $ 2.61 per share and $ 4.06 per share, respectively. The total fair value of options vested during the years ended December 31, 2023 and 2022 was $ 6.7 million and $ 6.9 million, respectively. Upon option exercise, the Company issues new shares of its common stock. The assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows: Years ended December 31, 2023 2022 Expected volatility 77.9 % 74.9 % Risk-free interest rate 3.89 % 2.14 % Expected dividend yield 0.0 % 0.0 % Expected term 6.05 years 6.04 years Expected volatility. As the Company’s common stock does not have a significant trading history, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. Risk-free interest rate. The Company bases the risk-free interest rate assumption on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present plans to pay cash dividends. Expected term. For employees, the expected term represents the period of time that options are expected to be outstanding. Because the Company has minimal historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. For nonemployees, the expected term is generally the contractual term of the option. Employee Stock Purchase Plan In December 2020, the Company’s board of directors and stockholders approved the BioAtla, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP permits participants to purchase common stock through payroll deductions of up to 15 % of their eligible compensation. As of December 31, 2023 and 2022 , a total of 1,737,098 and 1,229,148 shares, respectively, of common stock were authorized for issuance under the ESPP. The number of shares of common stock authorized for issuance will automatically increase on January 1 of each calendar year, from January 1, 2021 through January 1, 2030 by the least of (i) 1.0 % of the total number of common shares of our common stock outstanding on December 31 of the preceding calendar year (calculated on a fully diluted basis), (ii) 929,658 common shares or (iii) a number determined by the Company’s board of directors that is less than (i) and (ii) . During the years ended December 31, 2023 and 2022 , the Company issued 165,550 and 147,564 shares of common stock under the ESPP, respectively. As of December 31, 2023 , 1,412,802 shares of common stock remained available for issuance under the ESPP. Stock-based compensation expense related to the ESPP for the twelve months ended December 31, 2023 and 2022 was $ 0.2 million, respectively. Common stock reserved for future issuance Common stock reserved for future issuance are as follows in common equivalent shares: December 31, 2023 2022 Common stock options and restricted stock units issued and outstanding 6,372,611 3,246,957 Awards available for future issuance under the 2020 Plan 991,413 3,012,554 Awards available for future issuance under the ESPP 1,412,802 1,070,402 Total common stock reserved for future issuance 8,776,826 7,329,913 |
Collaboration, license and opti
Collaboration, license and option agreements | 12 Months Ended |
Dec. 31, 2023 | |
Collaboration License And Option Agreements [Abstract] | |
Collaboration, license and option agreements | . Collaboration, license and option agreements Global Co-Development and Collaboration Agreement with BeiGene In April 2019, the Company entered into a Global Co-Development and Collaboration agreement (the “BeiGene Collaboration”) with BeiGene, Ltd. and BeiGene Switzerland GmbH (collectively “BeiGene”), for the development, manufacturing and commercialization of the Company’s investigational CAB CTLA-4 antibody (evalstotug, BA3071). The BeiGene Collaboration was amended several times between 2019 and 2021 and the Company received a total of $ 25.0 million in non-refundable payments from BeiGene during that time. In November 2021, the BeiGene Collaboration was terminated, subject to survival of certain provisions, and BeiGene handed back rights to know-how and materials received under the amended BeiGene Collaboration. As a result, the Company is responsible for the global development and commercialization of evalstotug. As consideration for this amendment, the Company agreed to pay BeiGene mid-single digit royalties on sales worldwide and on a limited basis will share in any upfront and milestone payments received through a sublicense of evalstotug. The Company reclassified its then remaining $ 19.8 million of deferred revenue as a long-term liability which is expected to settle as licensing payments are made to BeiGene in accordance with the resulting amendment. In the event the license is terminated, the liability will be extinguished with no further payment to BeiGene. The Company did no t recognize any revenue related to the collaboration agreement with BeiGene for the years ended December 31, 2023 and 2022. The Company had a $ 19.8 million Liability to Licensor as of December 31, 2023 and 2022. Collaboration and Supply Agreement with Bristol-Myers Squib In January 2022, the Company and Bristol-Myers Squibb Company (“BMS”) entered into a clinical trial collaboration and supply agreement (the “BMS Agreement”). Under the terms of the BMS Agreement, BioAtla and BMS will collaborate on clinical trials of separate combination therapies using two of BioAtla’s Conditionally Active Biologic Antibody Drug Conjugates, mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021), each in combination with Opdivo® (nivolumab), BMS’ proprietary anti-PD-1 monoclonal antibody product. The Company will serve as the study sponsor of the scheduled studies and will be responsible for costs associated with the trial execution. BMS will provide Opdivo® clinical drug supply at no cost for the combination study trials. After the completion of the combination therapy trials, the Company is obligated to provide BMS with a final report of the data resulting from the trial. The BMS Agreement was amended in October 2022 to include additional territories for our mecbotamab vedotin and ozuriftamab vedotin combination study trials. There was no impact to the Company's financial results for the years ended December 31, 2023 or 2022 as a result of this agreement. |
Related party transactions
Related party transactions | 12 Months Ended |
Dec. 31, 2023 | |
Related Party Transactions [Abstract] | |
Related party transactions | . Related party transactions Inversagen, LLC On March 15, 2019, the Company entered into an Exclusive License Agreement with Inversagen (the “Inversagen License”). Under the terms of the agreement, Inversagen acquired the rights to CAB-antibodies for the field of diseases associated with aging, outside of cancer, and an immuno-oncology antibody. The Company may perform development services under the agreement and will be reimbursed by Inversagen for its costs. Commencing on the first commercial sale of the CAB-antibodies and immuno-oncology antibody subject to the Inversagen License, Inversagen will pay the Company milestone payments and royalties, which represent a variable interest held by the Company. On July 7, 2020, the Company and Inversagen entered into the First Amendment to Exclusive License Agreement (“Amended Inversagen License”), which grants the Company an option for a period of 10 years to acquire the immuno-oncology antibody in return for royalty payments in the low-single digits during the applicable royalty term. No payments have been made to date. Inversagen has only nominal assets and liabilities and is a VIE as the entity lacks sufficient equity to finance its activities without additional subordinated financial support. The Company does not consolidate Inversagen as it is not the primary beneficiary; the Inversagen License and the Amended Inversagen License did not and do not provide the Company with any decision-making power over the activities that are most significant to the entity’s economic success, such as the direction of its development efforts or the search for or terms of any future financing arrangements. The Company has no equity interest in Inversagen, and no exposure to its losses. The Company has not provided any services to Inversagen, has not provided any support to Inversagen and has no obligation to do so, and Inversagen’s creditors have no recourse to the general credit of the Company. The Company does no t have any assets or liabilities associated with its variable interest in Inversagen at December 31, 2023 and 2022. Inversagen is a related party of the Company. Dr. Jay Short and his spouse serve as managers of Inversagen. BioAtla Holdings, LLC Effective January 1, 2020, the Company entered into an Exclusive License Agreement (the “BioAtla Holdings License”) with BioAtla Holdings, LLC. Under the terms of the agreement, BioAtla Holdings acquired the rights to CAB antibodies for certain targets in the field of Adoptive Cell Therapy (CAR-T format) in exchange for potential royalty payments on future net sales. On July 7, 2020, the Company and BioAtla Holdings entered into the First Amendment to Exclusive License Agreement (the “Amended BioAtla Holdings License”), which grants the Company an option for a period of 10 years to acquire the ACT Preparations and ACT Treatments in return for royalty payments in the low-single digits during the applicable royalty term. The Company has not exercised its option and no payments have been made to date under these agreements. In addition, effective January 1, 2020, the Company entered into a Royalty Sharing Agreement whereby the Company agreed to share with BioAtla Holdings 50 % of the royalties it receives from its Exclusive License Agreement with EXUMA Biotech Corp. BioAtla Holdings is a variable interest entity as it does not have sufficient equity to finance its activities without additional subordinated financial support. The royalty payments and option to acquire assets represent variable interests held by the Company in BioAtla Holdings. The Company is not the primary beneficiary of BioAtla Holdings, however, as the BioAtla Holdings License and Amended BioAtla Holdings License did not and do not provide the Company with any decision-making power over the activities that are most significant to the entity’s economic success, such as the direction of its development efforts or the search for or terms of any future financing arrangements. The Company has no equity interest in BioAtla Holdings, and no exposure to its losses. BioAtla Holdings is currently inactive, and the Company has not provided any support to BioAtla Holdings and has no obligation to do so, and BioAtla Holdings’ creditors have no recourse to the general credit of the Company. The Company does no t have any assets or liabilities associated with its variable interests in BioAtla Holdings at December 31, 2023 and 2022. BioAtla Holdings is a related party of the Company. Dr. Jay Short and his spouse serve as managers of BioAtla Holdings. Himalaya Therapeutics SEZC Exclusive Rights Agreement On January 1, 2020, the Company entered into an Amended and Restated Exclusive Rights Agreement (the “Amended Rights Agreement”) with Himalaya Therapeutics SEZC. Under the terms of the Amended Rights Agreement, Himalaya Therapeutics SEZC acquired the rights to 10 CAB-antibodies for the territory of China, Macao, Hong Kong and Taiwan, global rights to a CAB-HER2-bispecific-antibody and global co-development rights with the Company to an IL-22 non-CAB-antibody. Payments to the Company may include upfront payments, milestone payments and double digit royalties, which represent a variable interest held by the Company, but no payments have been made to the Company to date. Himalaya Therapeutics SEZC is a VIE as it does not have sufficient equity to finance its activities without additional subordinated financial support. The Company is not obligated to provide financial support to Himalaya Therapeutics SEZC. The Company is not the primary beneficiary of Himalaya Therapeutics SEZC, however, as the Amended Rights Agreement does not provide BioAtla, Inc. with the power to direct activities of a VIE that most significantly impact the VIE’s economic performance, such as decision-making power over the direction of its development efforts or the search for or terms of any future financing arrangements. The Company does no t have any assets or liabilities recorded at December 31, 2023 associated with its variable interest in Himalaya Therapeutics SEZC, and has no exposure to Himalaya Therapeutics SEZC losses. Himalaya Therapeutics SEZC is a related party as Dr. Jay Short and his spouse serve as directors, and Dr. Short's spouse also serves as an officer of such entity. Clinical Trial Services Agreement In April 2022, the Company entered into a Clinical Trial Agreement with Himalaya Therapeutics SEZC. Under the agreement, Himalaya Therapeutics SEZC agreed to provide services related to the initiation of clinical trials for mecbotamab vedotin in the People’s Republic of China. For the first year following effectiveness of the agreement, the Company has agreed to pay Himalaya Therapeutics SEZC for the full-time use of two of its personnel. Payments were due and payable by BioAtla to Himalaya Therapeutics SEZC on a quarterly calendar basis and are non-refundable. The Company made its final payment under the agreement in January 2023. For the twelve months ended December 31, 2023 and 2022, the Company recognized $ 0.1 million and $ 0.4 million in research and development expense related to the Clinical Trial Agreement, respectively. The Company did not have any amounts due from or due to Himalaya Therapeutics SEZC as of December 31, 2023 . In January 2024, the Clinical Trial Agreement was amended to extend the agreement for 12 additional months. Under the amended agreement, BioAtla will pay Himalaya Therapeutics SEZC for the full-time use of two of its personnel and provide services related to the initiation of clinical trials for evalstotug in China. Himalaya Parent LLC Dr. Jay Short and his spouse serve as managers of Himalaya Parent LLC. The Company does not have a variable interest in Himalaya Parent LLC. November 2022 Underwritten Offering As part of the 2022 underwritten offering, the Company issued 2,998,500 shares of common stock for total net proceeds of $ 19.1 million to certain stockholders considered to be related parties. |
401(k) plan
401(k) plan | 12 Months Ended |
Dec. 31, 2023 | |
Retirement Benefits [Abstract] | |
401(k) plan | . 401(k) plan The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain matching contributions to the 401(k) plan. To date, the Company has no t made any matching contributions. |
Income taxes
Income taxes | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income taxes | . Income taxes A reconciliation of income tax expense computed at the U.S. federal statutory income tax rate to the Company’s income tax expense is as follows (in thousands): Years Ended December 31, 2023 2022 Tax computed at the federal statutory rate $ ( 25,927 ) $ ( 22,361 ) State income taxes, net of federal tax benefit ( 8 ) ( 6 ) Nondeductible executive compensation 99 685 Stock-based compensation 1,326 1,132 Research and development and orphan drug credits ( 6,205 ) ( 3,692 ) Uncertain tax positions 1,551 910 Other, net 228 ( 23 ) Valuation allowance 28,936 23,355 Income tax expense $ — $ — The Company’s net deferred tax assets (liabilities) are as follows (in thousands): Years Ended December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 25,034 $ 17,430 Liability to licensor 4,159 4,159 Goodwill 2,938 3,193 Lease liability 517 836 Accrued compensation 746 659 Research credit carryforwards 10,379 5,760 Section 174 cost capitalization 31,220 14,523 Section 59(e) cost capitalization 8,400 9,450 Stock-based compensation 2,790 1,628 Other 4 3 Gross deferred tax assets 86,187 57,641 Less: valuation allowance ( 85,642 ) ( 56,706 ) Total deferred tax assets 545 935 Deferred tax liabilities: Fixed assets ( 231 ) ( 426 ) Operating lease right-of-use asset ( 314 ) ( 509 ) Total deferred tax liabilities ( 545 ) ( 935 ) Net deferred tax assets $ — $ — A valuation allowance of approximately $ 85.6 million as of December 31, 2023 has been established to offset the deferred tax assets as the Company has determined that it is not more likely than not that these assets will be realized. The valuation allowance increased by approximately $ 28.9 million during 2023. At December 31, 2023 , the Company had federal and state net operating loss carryforwards of approximately $ 119.2 million and $ 0.2 million, respectively. The federal and state net operating losses can be carried forward indefinitely, subject to an 80% limitation against taxable income. The state net operating losses will begin to expire in 2042, unless previously utilized. At December 31, 2023 , the Company had federal and California research and development credit carryforwards of approximately $ 7.8 million and $ 2.7 million, respectively. The federal credit carryforwards will begin to expire in 2040 , unless previously utilized. The California credits will carry forward indefinitely. At December 31, 2023 , the Company also had federal orphan drug credit carryforwards of approximately $ 3.9 million. The orphan drug credit carryforwards will begin to expire in 2041 , unless previously utilized. Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss carryforwards may be limited in the event a cumulative change in ownership of more than 50 % occurs within a three-year period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of remaining tax attribute carryforwards available to offset future taxable income and income tax expense in future years may be significantly restricted or eliminated. Further, the Company’s deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC Section 382. Under the FASB's accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides further clarification on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company regularly evaluates the likelihood of recognizing the benefit for income tax positions taken in various federal and state filings by considering all relevant facts, circumstances, and information available. A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands): Years Ended December 31, 2023 2022 Unrecognized tax benefits - beginning $ 1,968 $ 1,011 Gross increases - tax positions in prior period 161 11 Gross increase – current-period tax positions 1,473 946 Unrecognized tax benefits - ending $ 3,602 $ 1,968 As of December 31, 2023 , the Company had gross unrecognized tax benefits of approximately $ 3.6 million, none of which would affect the Company’s effective tax rate due to the existence of the valuation allowance. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheet and has not recognized interest or penalties in the statements of operations and comprehensive income for the year ended December 31, 2023. The Company does not anticipate a significant change to its liability for unrecognized tax benefits within the next twelve months. The Company is subject to taxation in the United States and various state jurisdictions. The Company is subject to examination by tax authorities in those jurisdictions since 2020 and 2019, respectively, and forward. However, to the extent allowed by law, the taxing authorities may have the right to examine periods where NOLs and research and development credits were generated and carried forward, and make adjustments to the amount of the NOL and research credits carryforward amount. The Company is not currently under examination by any jurisdiction. |
Subsequent events
Subsequent events | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent events | 11. Subsequent events The Company has completed an evaluation of all subsequent events through March 26, 2024 for the financial statements as of and for the year ended December 31, 2023 to ensure these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. Except as described below or elsewhere in these financial statements, the Company has concluded that no subsequent event has occurred that requires disclosure. |
Organization and summary of s_2
Organization and summary of significant accounting policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Organization | Organization BioAtla, LLC was formed in Delaware in March 2007 and was converted to a Delaware corporation in July 2020 and renamed BioAtla, Inc. (the “Company”). The Company has a proprietary platform for creating biologics, including its conditionally active biologics (“CAB” or “CABs”). CABs have been designed to be active only under certain conditions found in diseased tissue, while remaining inactive in normal tissue. The Company is currently in clinical development of its two lead CAB antibody drug conjugates (“CAB ADC”) targeting AXL and ROR2 receptors, its CAB immune-oncology antibody targeting CTLA-4, and its CAB bispecific antibody targeting EpCAM. |
Basis of Presentation | Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). BioAtla, Inc. is a single legal entity with no consolidated variable interest entities ("VIEs") or subsidiaries (see Note 8). |
Liquidity and going concern | Liquidity and Going Concern The Company has incurred cumulative operating losses and negative cash flows from operations since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the development of its product candidates. As of December 31, 2023, the Company had an accumulated deficit of $ 416.3 million . The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, or other sources. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. In January 2023, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Jefferies LLC pursuant to which the Company may, from time to time at its sole discretion, sell shares of the Company’s common stock, with aggregate gross sales proceeds of up to $ 100.0 million. The Company has not sold any shares of its common stock under the Sales Agreement as of December 31, 2023. Management is required to perform a two-step analysis of the Company’s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2). Management’s assessment included the preparation of cash flow forecasts resulting in management’s conclusion that there is not substantial doubt about the Company’s ability to continue as a going concern as its current cash and cash equivalents will be sufficient to fund the Company’s operations for a period of at least one year from the issuance date of these financial statements. |
Variable interest entities | Variable Interest Entities (“VIE”) The Company consolidates entities in which it has a controlling financial interest. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a voting interest entity or a VIE. VIEs are entities in which (i) the total equity investment at risk is sufficient to enable the entity to finance its activities independently, (ii) the equity holders have the power to direct the activities of the entity that most significantly impact its economic performance, the obligation to absorb the losses of the entity and the right to receive the residual returns of the entity and (iii) the legal entity is structured with substantive voting rights. A VIE is an entity that lacks one or more of the characteristics of a voting interest entity. The Company has a controlling financial interest in a VIE when the Company has a variable interest or interests that provide it with (i) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company evaluates its relationships with its VIEs on an ongoing basis to determine whether or not it has a controlling financial interest (see Note 8). |
Use of estimates | Use of Estimates The Company’s financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to accruals for research and development costs, equity-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. |
Segment reporting | Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. |
Cash and cash equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash equivalents. Cash equivalents consist of highly rated securities including U.S. Government and U.S. Treasury money market funds, which are unrestricted as to withdrawal or use. The cash and cash equivalents balance as of December 31, 2023 and 2022 includes $ 50.4 million and $ 0 , respectively, invested in U.S. Government and U.S. Treasury money market funds. |
Concentration of risk | Concentrations of Risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and may invest cash that is not required for immediate operating needs in highly liquid instruments that bear minimal risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. |
Property and equipment | Property and Equipment Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful life of the related assets. Leasehold improvements are stated at cost and amortized on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful life of the leasehold improvements. Repairs and maintenance costs are charged to expense as incurred and expenditures that materially extend the useful lives of assets are capitalized. |
Impairment of long-lived assets | Impairment of Long-Lived Assets The Company reviews long-lived assets, such as property and equipment, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Fair value would be assessed using discounted cash flows or other appropriate measures of fair value. The Company has no t recognized any impairment losses for the years ended December 31, 2023 and 2022 . |
Leases | Leases The Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. The Company’s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease right-of-use (“ROU”) assets are based on the corresponding lease liability adjusted for any lease payments made at or before commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line basis over the lease term. Variable lease costs are not included in the calculation of the ROU asset and the related lease liability and are recognized as incurred. The Company has a single lease agreement with lease and non-lease components, which are accounted for as a single lease component. Payments for short-term leases, defined as leases with a term of twelve months or less, are expensed on a straight-line basis over the lease term. The Company does not currently have any short-term leases. Operating leases are included in operating lease right-of-use assets, operating lease liabilities, and operating lease liabilities, non-current on the Company’s balance sheets. The Company does not have any finance leases. |
Revenue recognition | Revenue Recognition The Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. The Company considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. A customer is a party that has entered into a contract with the Company, where the purpose of the contract is to obtain a product or a service that is an output of the Company’s ordinary activities in exchange for consideration. To be considered a contract, (i) the contract must be approved (in writing, orally, or in accordance with other customary business practices), (ii) each party’s rights regarding the product or the service to be transferred can be identified, (iii) the payment terms for the product or the service to be transferred can be identified, (iv) the contract must have commercial substance (that is, the risk, timing or amount of future cash flows is expected to change as a result of the contract), and (v) it is probable that the Company will collect substantially all of the consideration to which it is entitled to receive in exchange for the transfer of the product or the service. A performance obligation is defined as a promise to transfer a product or a service to a customer. The Company identifies each promise to transfer a product or a service (or a bundle of products or services, or a series of products and services that are substantially the same and have the same pattern of transfer) that is distinct. A product or a service is distinct if both (i) the customer can benefit from the product or the service either on its own or together with other resources that are readily available to the customer and (ii) the Company’s promise to transfer the product or the service to the customer is separately identifiable from other promises in the contract. Each distinct promise to transfer a product or a service is a unit of accounting for revenue recognition. If a promise to transfer a product or a service is not separately identifiable from other promises in the contract, such promises should be combined into a single performance obligation. The transaction price is the amount of consideration the Company is entitled to receive in exchange for the transfer of control of a product or a service to a customer. To determine the transaction price, the Company considers the existence of any significant financing component, the effects of any variable elements, noncash consideration and consideration payable to the customer. If a significant financing component exists, the transaction price is adjusted for the time value of money. If an element of variability exists, the Company must estimate the consideration it expects to receive and uses that amount as the basis for recognizing revenue as the product or the service is transferred to the customer. There are two methods for determining the amount of variable consideration: (i) the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts, and (ii) the mostly likely amount method, which identifies the single most likely amount in a range of possible consideration amounts. If a contract has multiple performance obligations, the Company allocates the transaction price to each distinct performance obligation in an amount that reflects the consideration the Company is entitled to receive in exchange for satisfying each distinct performance obligation. For each distinct performance obligation, revenue is recognized when the Company transfers control of the product or the service applicable to such performance obligation. In those instances where the Company first receives consideration in advance of satisfying its performance obligation, the Company classifies such consideration as deferred revenue until (or as) the Company satisfies such performance obligation. In those instances where the Company first satisfies its performance obligation prior to its receipt of consideration, the consideration is recorded as accounts receivable. The Company expenses incremental costs of obtaining and fulfilling a contract as incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as contract assets if they are incremental to the contract and amortized to expense proportionate to revenue recognition of the underlying contract. |
Research and development expenses | Research and Development Expenses The Company’s activities have largely consisted of research and development efforts related to developing our CAB programs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to expense as incurred. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in the accompanying balance sheets as prepaid or accrued expenses. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. As of December 31, 2023, the Company has accrued $ 12.5 million related to clinical trial costs. The Company has entered into contracts related to its clinical trials with clinical research organizations. The Company reviews and accrues clinical trial costs based on work performed, which relies on estimates and assumptions of total trial management costs, sites activated, patients enrolled, and number of patient visits. The Company follows this method since reasonably dependable estimates of the costs applicable to clinical trials can be made. Accrued clinical trial costs are subject to revisions as the trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. A modification in the protocol of a clinical trial or cancellation of a trial could result in a material change to the Company's results of operations. |
Patent costs | Patent Costs Costs related to filing and pursuing patent applications are recorded as general and administrative expenses and expensed as incurred since recoverability of such expenditures is uncertain. |
Stock-based compensation | Stock-Based Compensation Stock-based compensation expense represents the grant date fair value of equity awards, consisting of stock options, restricted stock units (“RSUs”) and employee stock purchase plan rights, over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of stock option grants and employee stock purchase plan rights using the Black-Scholes option pricing model. Prior to the Company’s IPO, the fair value of RSUs was based on the estimated fair value of the underlying common stock on the date of grant and, subsequent to the Company’s IPO, the fair value is based on the closing sales price of the Company’s common stock on the date of grant. Equity award forfeitures are recognized as they occur. |
Income taxes | Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as income in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, exclusive of reversing temporary difference, tax-planning strategies, and the results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 % likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. |
Comprehensive loss | Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss. |
Net loss per unit/share | Net Loss Per Share Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of RSUs, common stock options outstanding under the Company’s stock option plan, and contingently issuable shares under the BioAtla, Inc. Employee Stock Purchase Plan (the “ESPP”). Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalents): December 31, 2023 2022 Common stock options 6,273,507 2,736,918 Restricted stock units 99,104 510,039 ESPP Shares 57,253 13,370 Total 6,429,864 3,260,327 |
Recent accounting pronouncements | Recent Accounting Pronouncements In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. ASU 2023-09 requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. |
Organization and summary of s_3
Organization and summary of significant accounting policies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share | Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalents): December 31, 2023 2022 Common stock options 6,273,507 2,736,918 Restricted stock units 99,104 510,039 ESPP Shares 57,253 13,370 Total 6,429,864 3,260,327 |
Balance sheet details (Tables)
Balance sheet details (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of Prepaid Expenses Other Current Assets | Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2023 2022 Prepaid research and development $ 4,615 $ 4,385 Other prepaid expenses and current assets 320 539 Total $ 4,935 $ 4,924 |
Schedule of Property and Equipment | Property and equipment consist of the following (in thousands): December 31, Useful life (years) 2023 2022 Furniture, fixtures and office equipment 3 - 7 $ 1,721 $ 2,140 Laboratory equipment 5 2,280 2,265 Leasehold improvements 2 - 3 3,680 3,687 7,681 8,092 Less accumulated depreciation and amortization ( 6,078 ) ( 5,364 ) Total $ 1,603 $ 2,728 |
Schedule of Accounts Payable and Accrued Expenses | Accounts payable and accrued expenses consist of the following (in thousands): December 31, 2023 2022 Accounts payable $ 3,819 $ 4,231 Accrued compensation 3,790 3,451 Accrued research and development 18,246 12,649 Other accrued expenses 865 1,279 Total $ 26,720 $ 21,610 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Lessee Disclosure [Abstract] | |
Components of Lease Expense | The components of lease expense included in the Company’s statements of operations and loss include (in thousands): Years ended December 31, 2023 2022 Operating lease expense $ 1,043 $ 1,043 Variable lease expense 544 460 Total lease expense, net $ 1,587 $ 1,503 |
Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate | The weighted average remaining lease term and weighted average discount rate for operating leases were as follows: December 31, 2023 2022 Weighted average remaining lease term (in years) 1.5 2.5 Weighted average discount rate percentage 3.50 % 3.50 % |
Supplemental Cash Flow Information Related to Leases | Supplemental cash flow information related to leases under which the Company is the lessee was as follows (amounts in thousands): Years ended December 31, 2023 2022 Cash paid for amounts included in the measurement of operating leases $ 1,500 $ 1,555 |
Maturities of Operating Lease Liabilities | Maturities of operating lease liabilities as of December 31, 2023 were as follows (in thousands): Years ending December 31: Operating 2024 $ 1,685 2025 845 Thereafter — Total future lease payments 2,530 Less imputed interest ( 70 ) Total operating lease liabilities $ 2,460 |
Stockholders equity (Tables)
Stockholders equity (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Schedule of Stock-Based Compensation Expense | Stock-based compensation expense recognized for all equity awards under the 2020 Plan has been reported in the statements of operations and comprehensive loss as follows (in thousands): Years ended December 31, 2023 2022 Research and development $ 5,462 $ 5,419 General and administrative 8,082 9,144 Total $ 13,544 $ 14,563 |
Summary of Restricted Stock Units | The following table summarizes RSU activity under the 2020 Plan for the years ended December 31, 2023 and 2022: Number of Weighted - Outstanding at December 31, 2021 975,046 $ — Granted — $ — Vested ( 446,260 ) $ 18.00 Forfeited ( 18,747 ) Outstanding at December 31, 2022 510,039 $ 18.00 Granted 45,290 $ 2.35 Vested ( 433,948 ) $ 16.37 Forfeited ( 22,277 ) $ 18.00 Outstanding at December 31, 2023 99,104 $ 18.00 |
Summary of Stock Option Activity | The following table summarizes stock option activity under the 2020 Plan for the year ended December 31, 2023 and 2022 (in thousands, except share and per option data and years): Number of Weighted - Weighted - Aggregate Balance at December 31, 2021 1,086,902 $ 26.76 9.22 $ 991,495 Granted 1,718,200 $ 6.35 Exercised — $ — Forfeited ( 50,387 ) $ 21.64 Expired ( 17,797 ) $ 40.00 Balance at December 31, 2022 2,736,918 $ 13.82 8.82 $ 3,636,148 Granted 4,020,395 $ 3.74 Exercised — $ — Forfeited ( 371,439 ) $ 7.20 Expired ( 112,367 ) $ 20.96 Balance at December 31, 2023 6,273,507 $ 7.62 8.64 $ 74,680 Vested and expected to vest at December 31, 2023 6,273,507 $ 7.62 8.64 $ 74,680 Exercisable at December 31, 2023 1,429,449 $ 14.98 7.75 $ 2,007 |
Summary of Assumptions Used in Black-Scholes Model | The assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows: Years ended December 31, 2023 2022 Expected volatility 77.9 % 74.9 % Risk-free interest rate 3.89 % 2.14 % Expected dividend yield 0.0 % 0.0 % Expected term 6.05 years 6.04 years |
Schedule of Common Stock Reserved for Future Issuance | Common stock reserved for future issuance are as follows in common equivalent shares: December 31, 2023 2022 Common stock options and restricted stock units issued and outstanding 6,372,611 3,246,957 Awards available for future issuance under the 2020 Plan 991,413 3,012,554 Awards available for future issuance under the ESPP 1,412,802 1,070,402 Total common stock reserved for future issuance 8,776,826 7,329,913 |
Income taxes (Tables)
Income taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income Tax Reconciliation | A reconciliation of income tax expense computed at the U.S. federal statutory income tax rate to the Company’s income tax expense is as follows (in thousands): Years Ended December 31, 2023 2022 Tax computed at the federal statutory rate $ ( 25,927 ) $ ( 22,361 ) State income taxes, net of federal tax benefit ( 8 ) ( 6 ) Nondeductible executive compensation 99 685 Stock-based compensation 1,326 1,132 Research and development and orphan drug credits ( 6,205 ) ( 3,692 ) Uncertain tax positions 1,551 910 Other, net 228 ( 23 ) Valuation allowance 28,936 23,355 Income tax expense $ — $ — |
Schedule of Deferred Tax Assets and Liabilities | The Company’s net deferred tax assets (liabilities) are as follows (in thousands): Years Ended December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 25,034 $ 17,430 Liability to licensor 4,159 4,159 Goodwill 2,938 3,193 Lease liability 517 836 Accrued compensation 746 659 Research credit carryforwards 10,379 5,760 Section 174 cost capitalization 31,220 14,523 Section 59(e) cost capitalization 8,400 9,450 Stock-based compensation 2,790 1,628 Other 4 3 Gross deferred tax assets 86,187 57,641 Less: valuation allowance ( 85,642 ) ( 56,706 ) Total deferred tax assets 545 935 Deferred tax liabilities: Fixed assets ( 231 ) ( 426 ) Operating lease right-of-use asset ( 314 ) ( 509 ) Total deferred tax liabilities ( 545 ) ( 935 ) Net deferred tax assets $ — $ — |
Schedule of Unrecognized Tax Benefits | Years Ended December 31, 2023 2022 Unrecognized tax benefits - beginning $ 1,968 $ 1,011 Gross increases - tax positions in prior period 161 11 Gross increase – current-period tax positions 1,473 946 Unrecognized tax benefits - ending $ 3,602 $ 1,968 |
Organization and summary of s_4
Organization and summary of significant accounting policies - Additional Information (Details) | 1 Months Ended | 12 Months Ended | |
Jan. 31, 2023 USD ($) | Dec. 31, 2023 USD ($) shares | Dec. 31, 2022 USD ($) NumberOfSegment shares | |
Organization And Summary Of Significant Accounting Policies [Line Items] | |||
Entity Incorporation, State or Country Code | DE | ||
Company formation date | 2007-03 | ||
Common Stock, Shares, Issued | shares | 48,077,599 | 46,336,166 | |
Preferred Stock, Shares Issued | shares | 0 | 0 | |
Accumulated deficit | $ (416,263,000) | $ (292,801,000) | |
Maximum aggregate gross sale proceeds | $ 0 | $ 61,682,000 | |
Uncertain tax positions percentage | 50% | ||
Number of operating segment | NumberOfSegment | 1 | ||
Impairment losses | $ 0 | $ 0 | |
Cash and cash equivalents | 50,400,000 | 0 | |
Operating lease right-of-use-assets | 1,495,000 | 2,423,000 | |
Operating lease liabilities | 1,624,000 | 1,521,000 | |
Operating lease liabilities, less current portion | 836,000 | 2,460,000 | |
Accrued clinical trial cost | $ 12,500,000 | ||
Accumulated deficit | |||
Organization And Summary Of Significant Accounting Policies [Line Items] | |||
Accumulated deficit | $ 416,300,000 | ||
Maximum aggregate gross sale proceeds | $ 100,000,000 | ||
Class B Common Stock | |||
Organization And Summary Of Significant Accounting Policies [Line Items] | |||
Common Stock, Shares, Issued | shares | 0 | 1,211,959 |
Organization and summary of s_5
Organization and summary of significant accounting policies - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Numerator: | ||
Net Income (Loss) | $ (123,462) | $ (106,482) |
Denominator: | ||
Weighted-average shares of common stock outstanding, diluted | 47,777,568 | 38,927,268 |
Organization and summary of s_6
Organization and summary of significant accounting policies - Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from calculation of diluted net loss per share | 6,429,864 | 3,260,327 |
Common stock options | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from calculation of diluted net loss per share | 6,273,507 | 2,736,918 |
Restricted Stock Units (RSUs) | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from calculation of diluted net loss per share | 99,104 | 510,039 |
Employees Stock Purchase Plan Shares | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from calculation of diluted net loss per share | 57,253 | 13,370 |
Balance sheet details - Schedul
Balance sheet details - Schedule of Prepaid Expenses Other Current Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Balance Sheet Related Disclosures [Abstract] | ||
Prepaid research and development | $ 4,615 | $ 4,385 |
Other prepaid expenses and current assets | 320 | 539 |
Total | $ 4,935 | $ 4,924 |
Balance sheet details - Sched_2
Balance sheet details - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Property And Equipment [Line Items] | ||
Property and equipment, gross | $ 7,681 | $ 8,092 |
Less accumulated depreciation and amortization | (6,078) | (5,364) |
Total | 1,603 | 2,728 |
Furniture Fixtures and Office Equipment | ||
Property And Equipment [Line Items] | ||
Property and equipment, gross | $ 1,721 | $ 2,140 |
Laboratory Equipment | ||
Property And Equipment [Line Items] | ||
Property and equipment useful life | 5 years | 5 years |
Property and equipment, gross | $ 2,280 | $ 2,265 |
Leasehold Improvements | ||
Property And Equipment [Line Items] | ||
Property and equipment, gross | $ 3,680 | $ 3,687 |
Minimum | Furniture Fixtures and Office Equipment | ||
Property And Equipment [Line Items] | ||
Property and equipment useful life | 3 years | 3 years |
Minimum | Leasehold Improvements | ||
Property And Equipment [Line Items] | ||
Property and equipment useful life | 2 years | 2 years |
Maximum | Furniture Fixtures and Office Equipment | ||
Property And Equipment [Line Items] | ||
Property and equipment useful life | 7 years | 7 years |
Maximum | Leasehold Improvements | ||
Property And Equipment [Line Items] | ||
Property and equipment useful life | 3 years | 3 years |
Balance sheet details - Sched_3
Balance sheet details - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Balance Sheet Related Disclosures [Abstract] | ||
Accounts payable | $ 3,819 | $ 4,231 |
Accrued compensation | 3,790 | 3,451 |
Accrued research and development | 18,246 | 12,649 |
Other accrued expenses | 865 | 1,279 |
Total | $ 26,720 | $ 21,610 |
Fair value measurements - Addit
Fair value measurements - Additional Information (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Fair Value Disclosures [Abstract] | ||
Assets measured at fair value | $ 0 | $ 0 |
Liability measured at fair value | 0 | 0 |
Cash and Cash Equivalents | $ 50,400,000 | $ 0 |
Leases - Additional Information
Leases - Additional Information (Details) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Lessor Operating Leases Option To Extend | 5 years |
Lessor, operating lease, option to extend | The lease expires in July 2025 and the Company has an option to extend the term of the lease for an additional five years. Additionally, the lease includes certain rent abatement, rent escalations, tenant improvement allowances and additional charges for common area maintenance and other costs. |
Leases - Components of Lease Ex
Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Leases [Abstract] | ||
Operating lease expense | $ 1,043 | $ 1,043 |
Variable lease expense | 544 | 460 |
Total lease expense, net | $ 1,587 | $ 1,503 |
Leases - Summary of Weighted Av
Leases - Summary of Weighted Average Remaining Lease Term And Weighted Average Discount Rate (Details) | Dec. 31, 2023 | Dec. 31, 2022 |
Leases [Abstract] | ||
Weighted average remaining lease term (in years) | 1 year 6 months | 2 years 6 months |
Weighted average discount rate percentage | 3.50% | 3.50% |
Leases - Supplemental Cash Flow
Leases - Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Leases [Abstract] | ||
Cash paid for amounts included in the measurement of operating leases | $ 1,500 | $ 1,555 |
Leases - Maturities of Operatin
Leases - Maturities of Operating Lease Liabilities (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
Leases [Abstract] | |
2024 | $ 1,685 |
2025 | 845 |
Thereafter | 0 |
Total future lease payments | 2,530 |
Less imputed interest | (70) |
Total operating lease liabilities | $ 2,460 |
Stockholders' equity - Addition
Stockholders' equity - Additional Information (Details) - USD ($) | 1 Months Ended | 12 Months Ended | ||||||
Jan. 01, 2021 | Jan. 31, 2023 | Nov. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Nov. 08, 2022 | |
Class Of Stock [Line Items] | ||||||||
Common stock, shares issued | 48,077,599 | 46,336,166 | ||||||
Preferred stock, shares authorized | 200,000,000 | 200,000,000 | ||||||
Preferred stock, par value | $ 0.0001 | $ 0.0001 | ||||||
Common stock, shares authorized | 350,000,000 | 350,000,000 | ||||||
Common stock par value per share | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||
Conversion of stock, description | Holders of the Company’s common stock have no conversion rights, while holders of the Company’s Class B common stock shall have the right to convert each share of Class B common stock into one share of common stock at such holder’s election, provided that as a result of such conversion, such holder would not beneficially own in excess of 4.99% of any class of the Company’s securities registered under the Securities Exchange Act of 1934 | |||||||
Period related to changing of ownership limitation percentage designated by Class B common stock holder | 61 days | |||||||
Warrants expired and unexercised | 151,088 | 566,586 | ||||||
Vesting period | 450 days | 365 days | ||||||
Fair value of options, vested | $ 6,700,000 | $ 6,900,000 | ||||||
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition | 8 months 12 days | |||||||
Total number of common shares reserved for issuance | 8,776,826 | 7,329,913 | ||||||
Equity Option | ||||||||
Class Of Stock [Line Items] | ||||||||
Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount | $ 15,600,000 | |||||||
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition | 2 years 9 months 18 days | |||||||
Share-based compensation arrangement by share based payment award options grants in period weighted average grant date fair value | $ 2.61 | $ 4.06 | ||||||
Restricted Stock Units (RSUs) | ||||||||
Class Of Stock [Line Items] | ||||||||
Number of shares, vested | 433,948 | 446,260 | ||||||
Compensation expense on issuance of director compensation | $ 100,000 | |||||||
Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount | $ 1,800 | |||||||
Restricted Stock Units (RSUs) | Board of Directors | ||||||||
Class Of Stock [Line Items] | ||||||||
Number of shares, vested | 45,290 | |||||||
Open Market Sale Agreement | ||||||||
Class Of Stock [Line Items] | ||||||||
Maximum aggregate gross proceeds | $ 100,000,000 | |||||||
Common Stock Warrants | ||||||||
Class Of Stock [Line Items] | ||||||||
Vesting terms, description | The warrants became exercisable upon the Company's IPO for a period of 365 and 450 days | |||||||
2020 Equity Incentive Plan | ||||||||
Class Of Stock [Line Items] | ||||||||
Common shares authorized for issuance | 9,196,970 | 7,658,509 | ||||||
Shares available for awards, description | 4 | |||||||
Vesting percentage | 25% | |||||||
Vesting period | 36 months | |||||||
Vesting terms, description | ten years | |||||||
Compensation cost for the modified unvested restricted stock units | $ 416,000 | |||||||
Number of modified fully vested options | 130,699 | |||||||
Increase in compensation cost of fully vested options | $ 123,000 | |||||||
2020 Equity Incentive Plan | Restricted Stock Units (RSUs) | ||||||||
Class Of Stock [Line Items] | ||||||||
Total number of modified unvested restricted stock units | 139,730 | |||||||
Employees Stock Purchase Plan Shares | ||||||||
Class Of Stock [Line Items] | ||||||||
Common stock, shares issued | 165,550 | 147,564 | ||||||
Common stock, shares authorized | 1,737,098 | 1,229,148 | ||||||
Purchase common stock through payroll deductions of up to compensations, percent | 15% | |||||||
Share-based compensation arrangement by share based payment award percentage of outstanding stock maximum | 1% | |||||||
Increase in common stock authorized for issuance | 929,658 | |||||||
Total number of common shares reserved for issuance | 1,412,802 | |||||||
Stock-based compensation expense | $ 200,000 | |||||||
November 2022 Underwritten Offering | ||||||||
Class Of Stock [Line Items] | ||||||||
Sale of stock price per share | $ 6.67 | |||||||
Common stock, shares issued | 9,745,128 | |||||||
Proceeds from underwritten offering, net of underwriting discounts and commissions and other offering costs | $ 61,700 | |||||||
Class B Common Stock | ||||||||
Class Of Stock [Line Items] | ||||||||
Common stock, shares issued | 0 | 1,211,959 | ||||||
Common stock, shares authorized | 15,368,569 | 15,368,569 | ||||||
Common stock par value per share | $ 0.0001 | $ 0.0001 | ||||||
Common Stock | ||||||||
Class Of Stock [Line Items] | ||||||||
Common stock, voting rights | one | |||||||
Common Stock Options | 2020 Equity Incentive Plan | ||||||||
Class Of Stock [Line Items] | ||||||||
Total number of modified unvested options | 574,244 | |||||||
Compensation cost for the modified unvested options | $ 962,000 |
Stockholders' equity - Schedule
Stockholders' equity - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Class Of Stock [Line Items] | ||
Stock-based compensation | $ 13,544 | $ 14,563 |
Research and Development Expense | ||
Class Of Stock [Line Items] | ||
Stock-based compensation | 5,462 | 5,419 |
General and Administrative Expense | ||
Class Of Stock [Line Items] | ||
Stock-based compensation | $ 8,082 | $ 9,144 |
Stockholders' equity - Summary
Stockholders' equity - Summary of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) - $ / shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Class Of Stock [Line Items] | ||
Number of Outstanding Shares, Beginning Balance | 510,039 | 975,046 |
Number of Shares, Granted | 45,290 | 0 |
Number of Shares, Vested | (433,948) | (446,260) |
Number of Shares, forfeited | (22,277) | (18,747) |
Number of Outstanding Shares, Ending Balance | 99,104 | 510,039 |
Weighted Average Grant Date Fair Value, Beginning Balance | $ 18 | $ 0 |
Weighted Average Grant Date Fair Value, Granted | 2.35 | 0 |
Weighted Average Grant Date Fair Value, Vested | 16.37 | 18 |
Weighted Average Grant Date Fair Value, Forfeited | 18 | |
Weighted Average Grant Date Fair Value, Ending Balance | $ 18 | $ 18 |
Stockholders' equity - Summar_2
Stockholders' equity - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Stock Options Outstanding, Beginning Balance, Number of Shares | 2,736,918 | 1,086,902 | |
Exercised, Number of Shares | 0 | 0 | |
Forfeiture, Number of Shares | (371,439) | (50,387) | |
Expired, Number of Shares | (112,367) | (17,797) | |
Stock Options Outstanding, Ending Balance, Number of Shares | 6,273,507 | 2,736,918 | 1,086,902 |
Vested and expected to vest, Number of Shares | 6,273,507 | ||
Equity Option | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Granted, Number of Shares | 4,020,395 | 1,718,200 | |
Exercisable, Number of Shares | 1,429,449 | ||
Outstanding, Beginning Balance, Weighted-Average Exercise Price per Share | $ 13.82 | $ 26.76 | |
Granted, Weighted-Average Exercise Price per Share | 3.74 | 6.35 | |
Exercised, Weighted average exercise price per option | 0 | 0 | |
Forfeited, Weighted average exercise price per option | 7.2 | 21.64 | |
Expired, Weighted average exercise price per option | 20.96 | 40 | |
Exercisable, Weighted average exercise price per option | 14.98 | ||
Outstanding, Ending Balance, Weighted-Average Exercise Price per Share | $ / shares | 7.62 | $ 13.82 | $ 26.76 |
Vested and expected to vest, Weighted-Average Exercise Price per Share | $ 7.62 | ||
Outstanding, Weighted-Average Remaining Contractual Term (years) | 8 years 7 months 20 days | 8 years 9 months 25 days | 9 years 2 months 19 days |
Vested and expected to vest, Weighted-Average Remaining Contractual Term (years) | 8 years 7 months 20 days | ||
Exercisable, Weighted-Average Remaining Contractual Term (years) | 7 years 9 months | ||
Outstanding, Aggregate Intrinsic Value | $ 3,636,148 | $ 991,495 | |
Outstanding, Aggregate Intrinsic Value | 74,680 | $ 3,636,148 | $ 991,495 |
Vested and expected to vest, Aggregate Intrinsic Value | 74,680 | ||
Exercisable, Aggregate Intrinsic | $ 2,007 |
Stockholders' equity - Summar_3
Stockholders' equity - Summary of Assumptions Used in Black-Scholes Model (Details) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Stockholders' Equity Note [Abstract] | ||
Expected volatility | 77.90% | 74.90% |
Risk-free interest rate | 3.89% | 2.14% |
Expected dividend yield | 0% | 0% |
Expected term | 6 years 18 days | 6 years 14 days |
Stockholders' equity - Schedu_2
Stockholders' equity - Schedule of Common Stock Reserved for Future Issuance (Details) - shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Class Of Stock [Line Items] | ||
Common Stock, Shares, Issued | 48,077,599 | 46,336,166 |
Common Stock, Shares, Outstanding | 48,077,599 | 46,336,166 |
Total number of common shares reserved for issuance | 8,776,826 | 7,329,913 |
Common Stock Options and Restricted Stock Units [Member] | ||
Class Of Stock [Line Items] | ||
Common Stock, Shares, Issued | 6,372,611 | 3,246,957 |
Common Stock, Shares, Outstanding | 6,372,611 | 3,246,957 |
2020 Plan [Member] | ||
Class Of Stock [Line Items] | ||
Awards | 991,413 | 3,012,554 |
Employees Stock Purchase Plan Shares | ||
Class Of Stock [Line Items] | ||
Common Stock, Shares, Issued | 165,550 | 147,564 |
Awards | 1,412,802 | 1,070,402 |
Total number of common shares reserved for issuance | 1,412,802 |
Collaboration, license and op_2
Collaboration, license and option agreements - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | 36 Months Ended | ||||
Nov. 18, 2021 | Dec. 31, 2023 | Dec. 31, 2021 | Dec. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2022 | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
Collaboration Amendment Date | 2019-04 | |||||
Retained Earnings (Accumulated Deficit) | $ (416,263) | $ (292,801) | ||||
Liability to licensor | 19,806 | 19,806 | ||||
BeiGene | ||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||
Collaboration Amendment Date | 2021-11 | |||||
Upfront Non-Refundable Payment | $ 25,000 | |||||
Revenues | 0 | |||||
License termination information, Description | In the event the license is terminated, the liability will be extinguished with no further payment to BeiGene. | |||||
Current portion of deferred revenue | $ 19,800 | |||||
Liability to licensor | $ 19,800 | $ 19,800 |
Related party transactions - Ad
Related party transactions - Additional Information (Details) - USD ($) | 12 Months Ended | ||||
Jul. 07, 2020 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2020 | Jan. 01, 2020 | |
Related Party Transaction [Line Items] | |||||
Research and development expense | $ 103,731,000 | $ 79,347,000 | |||
Common Stock, Shares, Issued | 48,077,599 | 46,336,166 | |||
Related Party | November 2022 Underwritten Offering | |||||
Related Party Transaction [Line Items] | |||||
Common Stock, Shares, Issued | 2,998,500 | ||||
Net proceeds Issuance Of private placement | $ 19,100,000 | ||||
Inversagen L L C | |||||
Related Party Transaction [Line Items] | |||||
Royalty Expense | $ 0 | ||||
Options grants related to royalty payment, Period | 10 years | ||||
Assets or liabilities associated with related party variable interest | $ 0 | $ 0 | |||
Himalaya Therapeutics S E Z C | |||||
Related Party Transaction [Line Items] | |||||
Research and development expense | $ 100,000 | 400,000 | |||
Extended Rent Agreement | 12 months | ||||
Royalty Expense | $ 0 | ||||
Description Of Agreement With Related Party | In April 2022, the Company entered into a Clinical Trial Agreement with Himalaya Therapeutics SEZC. Under the agreement, Himalaya Therapeutics SEZC agreed to provide services related to the initiation of clinical trials for mecbotamab vedotin in the People’s Republic of China. For the first year following effectiveness of the agreement, the Company has agreed to pay Himalaya Therapeutics SEZC for the full-time use of two of its personnel. Payments were due and payable by BioAtla to Himalaya Therapeutics SEZC on a quarterly calendar basis and are non-refundable. The Company made its final payment under the agreement in January 2023. For the twelve months ended December 31, 2023 and 2022, the Company recognized $0.1 million and $0.4 million in research and development expense related to the Clinical Trial Agreement, respectively. The Company did not have any amounts due from or due to Himalaya Therapeutics SEZC as of December 31, 2023. | ||||
Assets or liabilities associated with related party variable interest | $ 0 | ||||
Bio Atla Holdings L L C | |||||
Related Party Transaction [Line Items] | |||||
Assets or liabilities associated with related party variable interest | $ 0 | $ 0 | |||
Options grants related to royalty payments, Period | 10 years | ||||
Share of Royalties under Royalty Sharing Agreement | 50% |
401(k) plan - Additional Inform
401(k) plan - Additional Information (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) | |
Retirement Benefits [Abstract] | |
Contributions made by company | $ 0 |
Income taxes - Schedule of Inco
Income taxes - Schedule of Income Tax Reconciliation (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
Tax computed at the federal statutory rate | $ (25,927) | $ (22,361) |
State income taxes, net of federal tax benefit | (8) | (6) |
Nondeductible executive compensation | 99 | 685 |
Stock-based compensation | (1,326) | 1,132 |
Research and development and orphan drug credits | (6,205) | (3,692) |
Uncertain tax positions | 1,551 | 910 |
Other, net | 228 | (23) |
Valuation allowance | 28,936 | 23,355 |
Income tax expense | $ 0 | $ 0 |
Income taxes - Schedule of Defe
Income taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets: | ||
Net operating loss carryforwards | $ 25,034 | $ 17,430 |
Liability to licensor | 4,159 | 4,159 |
Goodwill | 2,938 | 3,193 |
Lease liability | 517 | 836 |
Accrued compensation | 746 | 659 |
Research credit carryforwards | 10,379 | 5,760 |
Section 174 cost capitalization | 31,220 | 14,523 |
Section 59(e) cost capitalization | 8,400 | 9,450 |
Stock-based compensation | 2,790 | 1,628 |
Other | 4 | 3 |
Gross deferred tax assets | 86,187 | 57,641 |
Less valuation allowance | (85,642) | (56,706) |
Total deferred tax assets | 545 | 935 |
Deferred tax liabilities: | ||
Fixed assets | (231) | (426) |
Operating lease right-of-use asset | (314) | (509) |
Total deferred tax liabilities | (545) | (935) |
Net deferred tax assets | $ 0 | $ 0 |
Income taxes - Additional Infor
Income taxes - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Operating Loss Carryforwards [Line Items] | |||
Deferred tax asset valuation allowance | $ 85,642 | $ 56,706 | |
Change in Valuation Allowance | 28,900 | ||
state net operating loss carryforwards | 200 | ||
Tax credit limitation on use | The federal and state net operating losses can be carried forward indefinitely, subject to an 80% limitation against taxable income. The state net operating losses will begin to expire in 2042, unless previously utilized. | ||
Tax Credit Carryforward, Amount | 7,800 | ||
Orphan Drug Credit | $ 3,900 | ||
Use of annual operating loss carryforwards | Sections 382 and 383, annual use of the Company’s net operating loss carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. | ||
CARES Act NOL carryover/carryback offset to taxable income. | 50% | ||
Unrecognized tax benefits | $ 3,602 | $ 1,968 | $ 1,011 |
Domestic Tax Authority | |||
Operating Loss Carryforwards [Line Items] | |||
Operating Loss Carryforwards Expiration Period | 2040 | ||
orphan drug credit carryforwards Expiration Period | 2041 | ||
Domestic Tax Authority | Research and Development Tax Credit | |||
Operating Loss Carryforwards [Line Items] | |||
Federal net operating loss carryforward | $ 119,200 | ||
California Franchise Tax Board | Research and Development Tax Credit | |||
Operating Loss Carryforwards [Line Items] | |||
Tax Credit Carryforward, Amount | $ 2,700 |
Income taxes - Schedule of Unre
Income taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
Beginning Balance | $ 1,968 | $ 1,011 |
Gross increases - tax positions in prior period | 161 | 11 |
Gross increase - current-period tax positions | 1,473 | 946 |
Ending Balance | $ 3,602 | $ 1,968 |
Subsequent events - Additional
Subsequent events - Additional Information (Details) - $ / shares | Dec. 31, 2023 | Jan. 31, 2023 | Dec. 31, 2022 |
Subsequent Event [Line Items] | |||
Common stock par value per share | $ 0.0001 | $ 0.0001 | $ 0.0001 |